Research & Literature

Basics in Clinical Medical Nutrition.

Meier RF, Forbes A

Nestle Nutrition Institute workshop series 2015; (82()):1-16 doi:10.1159/000381997.

Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.

Mori S, Hidaka M, Kawakita T, et al.

PloS one 2016; (11(4)):e0154744 doi:10.1371/journal.pone.0154744.

[Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl].

Hardy J, Audouin-Pajot C, Abid A, et al.

Annales de dermatologie et de venereologie 2016; (143(12)):836-840 doi:10.1016/j.annder.2016.06.010.

ESPEN guidelines on definitions and terminology of clinical nutrition.

Cederholm T, Barazzoni R, Austin P, et al.

Clinical nutrition (Edinburgh, Scotland) 2017; (36(1)):49-64 doi:10.1016/j.clnu.2016.09.004.

Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Mendoza FA, Mansoor M, Jimenez SA

Expert opinion on orphan drugs 2016; (4(1)):31-47 doi:10.1517/21678707.2016.1114454.

Musculoskeletal MRI findings of juvenile localized scleroderma.

Eutsler EP, Horton DB, Epelman M, et al.

Pediatric radiology 2017; (47(4)):442-449 doi:10.1007/s00247-016-3765-x.

Methotrexate-induced pancytopenia: a case series of 46 patients.

Ajmani S, Preet Singh Y, Prasad S, et al.

International journal of rheumatic diseases 2017; (20(7)):846-851 doi:10.1111/1756-185X.13004.

Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood.

Ruiz-Matta JM, Flores-Bozo LR, Dominguez-Cherit J

Pediatric dermatology 2017; (34(4)):e164-e167 doi:10.1111/pde.13160.

Orthopedic complications of linear morphea: Implications for early interdisciplinary care.

Schoch JJ, Schoch BS, Werthel JD, et al.

Pediatric dermatology 2018; (35(1)):43-46 doi:10.1111/pde.13336.

Disabling pansclerotic morphoea of childhood.

Jamalpur I, Mogili HR, Koratala A

BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-222132.

Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach.

Marrani E, Foeldvari I, Lopez JA, et al.

Seminars in arthritis and rheumatism 2018; (48(3)):495-503 doi:10.1016/j.semarthrit.2018.03.003.

Development of minimum standards of care for juvenile localized scleroderma.

Constantin T, Foeldvari I, Pain CE, et al.

European journal of pediatrics 2018; (177(7)):961-977 doi:10.1007/s00431-018-3144-8.

Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.

Martini G, Fadanelli G, Agazzi A, et al.

Autoimmunity reviews 2018; (17(7)):727-734 doi:10.1016/j.autrev.2018.02.004.

Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma.

Agazzi A, Fadanelli G, Vittadello F, et al.

Pediatric rheumatology online journal 2018; (16(1)):37 doi:10.1186/s12969-018-0254-9.

Immunotherapy of systemic sclerosis.

Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI

Human vaccines & immunotherapeutics 2018; (14(11)):2559-2567 doi:10.1080/21645515.2018.1491508.

Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

Soh HJ, Samuel C, Heaton V, et al.

Rheumatology international 2019; (39(5)):933-941 doi:10.1007/s00296-019-04269-w.

Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change.

Teske NM, Jacobe HT

The British journal of dermatology 2020; (182(2)):398-404 doi:10.1111/bjd.18097.

Methotrexate overdose in clinical practice.

Pannu AK

Current drug metabolism 2019; (20(9)):714-719 doi:10.2174/1389200220666190806140844.

Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma.

Li SC, Torok KS, Rabinovich CE, et al.

The Journal of rheumatology 2020; (47(8)):1242-1252 doi:10.3899/jrheum.190311.

Advances in pediatric psychooncology.

Wiener L, Devine KA, Thompson AL

Current opinion in pediatrics 2020; (32(1)):41-47 doi:10.1097/MOP.0000000000000851.

Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.

Arthur M, Fett NM, Latour E, et al.

JAMA dermatology 2020; (156(5)):521-528 doi:10.1001/jamadermatol.2020.0035.

Changes in Disease Activity and Damage Over Time in Patients With Morphea.

O'Brien JC, Nymeyer H, Green A, Jacobe HT

JAMA dermatology 2020; (156(5)):513-520 doi:10.1001/jamadermatol.2020.0034.

Update on Management of Morphea (Localized Scleroderma) in Children.

George R, George A, Kumar TS

Indian dermatology online journal 2020; (11(2)):135-145 doi:10.4103/idoj.IDOJ_284_19.

Treatment in Juvenile Scleroderma.

Zulian F, Tirelli F

Current rheumatology reports 2020; (22(8)):45 doi:10.1007/s11926-020-00910-x.

Effects of sense and functionality changes in the hands on activity and participation in patients with juvenile scleroderma.

Dag A, Tarakci E, Adrovic A, Kasapcopur O

Modern rheumatology 2021; (31(3)):657-668 doi:10.1080/14397595.2020.1816612.

Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.

Martini G, Saggioro L, Culpo R, et al.

Rheumatology (Oxford, England) 2021; (60(3)):1387-1391 doi:10.1093/rheumatology/keaa392.

Consensus-based recommendations for the management of juvenile systemic sclerosis.

Foeldvari I, Culpo R, Sperotto F, et al.

Rheumatology (Oxford, England) 2021; (60(4)):1651-1658 doi:10.1093/rheumatology/keaa584.

Assessment of nutritional status in children with kidney diseases-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.

Nelms CL, Shaw V, Greenbaum LA, et al.

Pediatric nephrology (Berlin, Germany) 2021; (36(4)):995-1010 doi:10.1007/s00467-020-04852-5.

Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma.

Li SC, Higgins GC, Chen M, et al.

Rheumatology (Oxford, England) 2021; (60(12)):5724-5733 doi:10.1093/rheumatology/keab238.

Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts.

Ventéjou S, Schwieger-Briel A, Nicolai R, et al.

Frontiers in immunology 2021; (12()):656407 doi:10.3389/fimmu.2021.656407.

Predictors of family impact of juvenile localized scleroderma.

Milovanova K, Adly M, Lethebe BC, et al.

Pediatric dermatology 2021; (38(5)):1137-1142 doi:10.1111/pde.14683.

Evaluation of the Effectiveness of a Technology-Based Psychosocial Education and Counseling Program for Adolescent Survivors of Childhood Leukemia: A Randomized Controlled Trial.

Arpaci T, Altay N, Copur GY

Cancer nursing 2023; (46(1)):14-28 doi:10.1097/NCC.0000000000001091.

[Clinical Nutrition for the Medical Patient: From Screening to Diagnosis and Start of Nutritional Therapy].

Eilinger L, Arifi T, Dziadova V, Schuetz P

Praxis 2022; (111(7)):367-373 doi:10.1024/1661-8157/a003862.

Narrow-band reflectance spectrophotometry and infrared thermography for assessment of skin lesions in localized scleroderma.

Szczepanek M, Frątczak A, Polak K, Lis-Święty A

Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(12)):2451-2458 doi:10.1111/jdv.18483.

The Relationship between the Unmet Needs of Chinese Family Caregivers and the Quality of Life of Childhood Cancer Patients Undergoing Inpatient Treatment: A Mediation Model through Caregiver Depression.

Wang J, Coyte PC, Shao D, et al.

International journal of environmental research and public health 2022; (19(16)) doi:10.3390/ijerph191610193.

Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.

Baghdassarian H, Blackstone SA, Clay OS, et al.

The New England journal of medicine 2023; (388(24)):2241-2252 doi:10.1056/NEJMoa2202318.

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines.

Siegfried EC, Arkin LM, Chiu YE, et al.

Pediatric dermatology 2023; (40(5)):789-808 doi:10.1111/pde.15327.

Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.

Bhat R, Tonutti A, Timilsina S, et al.

Clinical reviews in allergy & immunology 2023; (65(1)):86-100 doi:10.1007/s12016-023-08963-3.

Systemic therapy in juvenile localized scleroderma.

Foeldvari I, Marrani E

Expert review of clinical immunology 2023; (19(10)):1225-1238 doi:10.1080/1744666X.2023.2237685.

Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis.

Xing E, Ma F, Wasikowski R, et al.

JCI insight 2023; (8(16)).

Role of imaging in morphea assessment: A review of the literature.

Khorasanizadeh F, Kalantari Y, Etesami I

Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2023; (29(7)):e13410 doi:10.1111/srt.13410.

Connective tissue nevus misdiagnosed as juvenile localized scleroderma.

Tirelli F, Giraudo C, Soliani M, et al.

Pediatric rheumatology online journal 2023; (21(1)):125 doi:10.1186/s12969-023-00913-9.

Caregiver Burden, Stress, and Relationship Cohesion Among Self-Identified Caregivers of Children with Pediatric Acute-Onset Neuropsychiatric Syndrome.

Tona JT, Ash J, Brown E, et al.

Journal of child and adolescent psychopharmacology 2023; (33(9)):378-386 doi:10.1089/cap.2023.0030.

Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale.

Li SC, Rabinovich CE, Becker ML, et al.

Arthritis care & research 2024; (76(5)):616-626 doi:10.1002/acr.25281.

Disabling pansclerotic morphoea: a century of discovery.

Hua VK, Chang J, Laxer RM, Broderick L

The British journal of dermatology 2025; (192(4)):585-596 doi:10.1093/bjd/ljae443.

Comparative study between fractional CO2 laser (10,600 nm) and microneedling in treatment of morphea: dermoscopic and histopathological evaluation.

El-Shahawy MM, Farag AS, El-Khalawany MA, Pessar DAH

Archives of dermatological research 2025; (317(1)):276 doi:10.1007/s00403-024-03674-x.

Psychosocial Interventions to Improve Wellbeing in Teenage and Young Adult Post-Treatment Survivors of Childhood Cancer: A Systematic Review.

O'Donnell N, Ellis L, Morgan JE, et al.

Psycho-oncology 2025; (34(2)):e70081 doi:10.1002/pon.70081.

Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center.

Egeli BH, Dallas J, Reusch DB, et al.

Pediatric rheumatology online journal 2025; (23(1)):63 doi:10.1186/s12969-025-01116-0.

Assessing Psychological Harms on Parents and Primary Caregivers of Children Living with a Rare Disease: A Systematic Review of the Scope and Validity of Surveys Utilized.

Bull LJ, Eslick GD, Teutsch SM, Elliott EJ

Clinical child and family psychology review 2025; (28(3)):612-630 doi:10.1007/s10567-025-00533-7.

Coexistence of Localized and Systemic Juvenile Scleroderma: A Case Report and Review of Literature.

Miremarati A, Babaeian Roshani K, Tabrizi M, et al.

Clinical case reports 2025; (13(10)):e71078 doi:10.1002/ccr3.71078.

Psychological adjustment in parents of children and adolescents with chronic health conditions during the COVID-19 pandemic - a meta-analysis.

Göldel JM, Warschburger P

Health psychology review 2026; (20(2)):453-481 doi:10.1080/17437199.2026.2616461.

Successful tocilizumab-based combination therapy for a case of rapidly progressive adult deep morphea with multiple antiphospholipid antibodies: a case report and literature review.

Yu R, Zhang L, Li SG, et al.

Frontiers in immunology 2026; (17()):1764835 doi:10.3389/fimmu.2026.1764835.

Pediatric morphea: MRI evaluation of superficial and deep tissue involvement and impact in clinical practice.

Reyes Recasens MP, Pope EI, Sibbald C, et al.

Pediatric radiology 2026; (56(7)):1547-1560 doi:10.1007/s00247-026-06647-6.

Comparison of parental caregivers and associated factors with caregiver burden in rare paediatric diseases.

Brandt M, Inhestern L, Zybarth D, et al.

Orphanet journal of rare diseases 2026; (21(1)).